Navigation Links
Epizyme Receives Orphan Drug Designation for EPZ-5676
Date:8/16/2013

CAMBRIDGE, Mass., Aug. 16, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for EPZ-5676. Criteria for orphan drug designation requires that the product be intended for treatment of a rare disease or condition, classified as affecting fewer than 200,000 people in the United States.

Orphan drug designation allows special incentives for sponsors planning to test a product for use in a rare disease or condition. These incentives include tax credits, research and development grant funding and reduced filing fees during development or at the time of application for marketing approval. Once approved, the product may qualify for seven years of marketing exclusivity independent of any other intellectual property.

About EPZ-5676

Epizyme is developing EPZ-5676, a small molecule inhibitor of DOT1L created with Epizyme's proprietary product platform, for the treatment of acute leukemias in which the MLL gene is rearranged due to a chromosomal translocation (MLL-r). Due to the translocation, DOT1L is recruited to specific locations in the chromosome where it would not normally be present. As a result, DOT1L causes inappropriate methylation at these locations, which results in the increased expression of genes causing leukemia.

In September 2012, Epizyme initiated a Phase 1 clinical trial for EPZ-5676. The company believes EPZ-5676 is the first HMTi to enter human clinical development. As of August 2013, this program is in the dose escalation phase and is expected to initiate an expansion phase in the second half of 2013 that wil
'/>"/>

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
2. Epizyme to Present at Upcoming Conferences in February
3. Epizyme to Partner to Develop DOT1L Companion Diagnostic
4. Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Epizyme, Inc. Announces Pricing of Initial Public Offering
6. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
7. Epizyme, Inc. to Webcast Conference Call Discussing Second Quarter 2013 Financial Results on July 31, 2013
8. Epizyme, Inc. to Present at Wedbush Securities Life Sciences Management Access Conference in August
9. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
10. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
11. Nephros Receives 510(k) Clearance for Hemodiafiltration System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  ANI Pharmaceuticals, ... announced that it has acquired the approved abbreviated ... USP 50mg, 100mg and 150mg, previously marketed by ... market for this product was approximately $39 million ... Przybyl , President and CEO of ANI Pharmaceuticals, ...
(Date:3/5/2015)... Mar. 05, 2015 Research and Markets ... of the "Global Pharma US & EU ... Plays Major Role In Shaping Up Business for ... offering. Strategy Diversification Divested: Productivity ... Cash position- Will accelerate Next wave of targeted ...
(Date:3/5/2015)...  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), ... of targeted antiviral therapies, announced today that it will ... to be held March 8-11, 2015, in ... Sapirstein , Chief Executive Officer, will provide an overview ... will be available to participate in one-on-one meetings with ...
Breaking Medicine Technology:ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies 2Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies 3ContraVir to Present at 27th Annual ROTH Conference 2
... health has won out over the actions of a ... Jane L. Delgado, President and CEO of the National ... Hispanic health advocacy group. Commenting on actions taken by ... the Federal Trade Commission (FTC) to halt fraudulent claims, ...
... MiMedx Group, Inc. (OTCBB: MDXG), an integrated ... products and bioimplants processed from human amniotic membrane, ... the Company,s latest biologic implant processed to offer ... Produced from the MiMedx Group,s proprietary Purion® ...
Cached Medicine Technology:FDA Moves to Stop Bogus Products Sold Over the Counter and Online that Falsely Claim to Cure and Treat STDs 2MiMedx Announces Launch of AmnioFix™ Nerve Wrap 2
(Date:3/5/2015)... 05, 2015 As a result ... review of Clearstream, LLC ’s products, services ... MediDefense line of products—led by their mPulse Hand ... Partner Program. , The AAPA—which represents a profession ... medical and surgical specialties in the U.S.—advocates and ...
(Date:3/5/2015)... 05, 2015 Today, Earth Source ... on 100% pollution-free electricity through a partnership with ... As an Arcadia Power Clean Energy Partner, ESO ... Power Partnership requirements, joining national brands such as ... clean energy. Earth Source Organics joins a growing ...
(Date:3/5/2015)... March 05, 2015 The Journal ... released a special issue devoted entirely ... of PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with ... autoimmune reaction triggered by infections such as strep ... in inflammation of the child's brain. This inflammation ...
(Date:3/5/2015)... March 05, 2015 Think it’s tough to ... tougher to get them to brush their teeth. That’s a ... released today by Delta Dental(1) in conjunction with National Parenting ... percent) say getting kids to brush their teeth is one ... do. That’s slightly higher than getting children to eat vegetables ...
(Date:3/5/2015)... Florida (PRWEB) March 05, 2015 ... organization which provides vascular, echocardiogram and NCV ... F.A.C.C. as the Chief Medical Officer. Dr. Artel will ... the development of the WimbledonMED program and the continued ... been passionate about working with Wimbledon Health Partners as ...
Breaking Medicine News(10 mins):Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3
... may want to talk to their doctors about whether to stay ... provides strong evidence that the use of HRT is associated with ... puts women at a great risk. The study also reports an ... HRT compared to those who have not. ,Between 20 percent ...
... drugs do prevent the onset of Parkinson’s disease. The study, ... anti-inflammatory drugs (NSAIDs) had a lower risk of Parkinson’s than ... is characterized by the death of neurons in the brain. ... appear to be protective in animal studies and they also ...
... who take certain types of painkillers, including aspirin, are ... said on Friday. But Paracetomol is not a risk, ... they added. ,Researchers in California interviewed more than 1,000 ... about their reproductive history and their use of painkillers. ...
... long and how well children survive cancer. ,The first ... chemotherapy but not radiation to the brain area tended ... life than those who got both treatments. But the ... study found the risk of hospitalization for psychiatric disorders ...
... has been shown to boost vitamin D levels and ... of disease. Higher sun exposure during childhood and early ... sclerosis, according to the study. ,Australian investigators conducted a ... and has a high prevalence of multiple sclerosis. //Researchers ...
... helps brain cells function normally also protects against Alzheimer's, ... to better treatments for the illness. ,Brain cells ... researchers in the United States, who identified it in ... protein in the brain which are a characteristic sign ...
Cached Medicine News:
... is a suture option for ... diameter looped FiberWire products allow ... extensor tendon repairs while reducing ... passes. FiberLoop is available with ...
... study remains the mainstay in a urologic workup. ... patient needs for an accurate, easy-to-use in-office uroflow ... onset of urine flow and automatically ends when ... urine flow. There is no need to have ...
UroPass Open Tip Ureteral Stents perfect over-the-wire placement with a combination of flexibility and rigidity for comfort and control. When it comes to stent designs, UroPass is a proven leader....
... Ureteral Stents feature teardrop shaped kidney curls ... hydrophilic coating for ease of placement, and ... the trigone. The Multi-Flex advanced design has ... segment provides pushability for placement, and strength ...
Medicine Products: